Enanta Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US29251M1062

SecurityENTA / Enanta Pharmaceuticals, Inc.
InstitutionD. E. Shaw & Co., Inc.
ManagerDE Shaw
Latest Disclosed Ownership70,884 shares
Latest Disclosed Value $ 895,265
D. E. Shaw & Co., Inc. ownership in ENTA / Enanta Pharmaceuticals, Inc.

On May 15, 2026 - D. E. Shaw & Co., Inc. filed a 13F-HR form disclosing ownership of 70,884 shares of Enanta Pharmaceuticals, Inc. (US:ENTA) valued at $895,265 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 167,714 shares of Enanta Pharmaceuticals, Inc.. This represents a change in shares of -57.74% during the quarter. The current value of the position is $796,736 USD.

D. E. Shaw & Co., Inc. has a history of taking positions in derivatives of the underlying security (ENTA) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

ENTA / Enanta Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 70,884 -96,830 -57.74 895 -66.15 0.0004
2026-02-17 2025-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 167,714 -58,030 -25.71 2,645 -2.15 0.0014
2025-11-14 2025-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 225,744 -56,532 -20.03 2,702 26.62 0.0015
2025-08-14 2025-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 282,276 -101,044 -26.36 2,134 0.90 0.0015
2025-05-15 2025-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 383,320 -38,274 -9.08 2,116 -12.75 0.0019
2025-02-14 2024-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 421,594 -79,778 -15.91 2,424 -53.33 0.0018
2024-11-14 2024-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 501,372 -32,809 -6.14 5,194 -25.03 0.0045
2024-08-14 2024-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 534,181 -36,065 -6.32 6,928 -30.41 0.0065
2024-05-15 2024-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 570,246 -67,922 -10.64 9,956 65.80 0.0085
2024-02-14 2023-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 638,168 277,116 76.75 6,005 48.93 0.0052
2023-11-14 2023-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 361,052 308,503 587.08 4,033 258.72 0.0042
2023-08-14 2023-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 52,549 52,549 1,125 0.0011
2023-05-15 2023-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 0 -4,741 -100.00 0 -100.00
2023-02-14 2022-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 4,741 0 0.00 221 -10.57 0.0002
2022-11-14 2022-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 4,741 0 0.00 246 9.82 0.0003
2022-08-15 2022-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 4,741 -1,364 -22.34 224 -48.51 0.0003
2022-05-16 2022-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 6,105 -18,403 -75.09 435 -76.27 0.0004
2022-02-14 2021-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 24,508 14,172 137.11 1,833 212.27 0.0015
2021-11-15 2021-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 10,336 -14,404 -58.22 587 -46.10 0.0005
2021-08-16 2021-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 24,740 -16,444 -39.93 1,089 -46.38 0.0009
2021-05-17 2021-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 41,184 18,975 85.44 2,031 117.22 0.0020
2021-02-16 2020-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 22,209 -2,117 -8.70 935 -16.07 0.0008
2020-11-16 2020-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 24,326 9,512 64.21 1,114 49.73 0.0011
2020-08-14 2020-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 14,814 14,814 744 0.0009
2020-05-15 2020-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 0 -8,068 -100.00 0 -100.00
2020-02-14 2019-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 8,068 -3,229 -28.58 498 -26.66 0.0006
2019-11-14 2019-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 11,297 8,614 321.06 679 200.44 0.0008
2019-08-14 2019-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 2,683 2,683 226 0.0003
2019-05-15 2019-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 0 -5,250 -100.00 0 -100.00
2019-02-14 2018-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 5,250 -1,200 -18.60 372 -32.49 0.0005
2018-11-14 2018-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 6,450 -25,815 -80.01 551 -85.26 0.0007
2018-08-14 2018-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 32,265 1,974 6.52 3,739 52.55 0.0049
2018-05-15 2018-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 30,291 16,917 126.49 2,451 212.23 0.0033
2018-02-14 2017-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 13,374 -6,258 -31.88 785 -14.58 0.0011
2017-11-14 2017-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 19,632 -19,104 -49.32 919 -34.07 0.0014
2017-08-14 2017-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 38,736 22,930 145.07 1,394 186.24 0.0023
2017-05-15 2017-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 15,806 -15,184 -49.00 487 -53.08 0.0009
2017-02-14 2016-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 30,990 -56,349 -64.52 1,038 -55.34 0.0018
2016-11-14 2016-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 87,339 87,339 0.00 2,324 0.0041
2015-02-17 2014-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 0 -5,673 -100.00 0 -100.00
2014-11-14 2014-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 5,673 5,673 224 0.0003
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2018-11-14 2018-09-30 13F ENANTA PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2018-08-14 2018-06-30 13F ENANTA PHARMACEUTICALS COM Call 5,000 0.00 580 43.21 n/a n/a n/a
2018-05-15 2018-03-31 13F ENANTA PHARMACEUTICALS COM Call 5,000 405 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2020-08-14 2020-06-30 13F ENANTA PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2020-05-15 2020-03-31 13F ENANTA PHARMACEUTICALS COM Put 10,000 0.00 514 -16.83 n/a n/a n/a
2020-02-14 2019-12-31 13F ENANTA PHARMACEUTICALS COM Put 10,000 0.00 618 2.83 n/a n/a n/a
2019-11-14 2019-09-30 13F ENANTA PHARMACEUTICALS COM Put 10,000 601 n/a n/a n/a
2019-02-14 2018-12-31 13F ENANTA PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2018-11-14 2018-09-30 13F ENANTA PHARMACEUTICALS COM Put 10,000 0.00 855 -26.23 n/a n/a n/a
2018-08-14 2018-06-30 13F ENANTA PHARMACEUTICALS COM Put 10,000 0.00 1,159 43.26 n/a n/a n/a
2018-05-15 2018-03-31 13F ENANTA PHARMACEUTICALS COM Put 10,000 809 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.